Hao, Yanjie and Hansen, Dylan and Louthrenoo, Worawit and Chen, Yi-Hsing and Cho, Jiacai and Lateef, Aisha and Hamijoyo, Laniyati and Luo, Shue-Fen and Wu, Yeong-Jian Jan and Navarra, Sandra and Zamora, Leonid and Li, Zhanguo and Sockalingam, Sargunan and Katsumata, Yasuhiro and Harigai, Masayoshi and Zhang, Zhuoli and Chan, Madelynn and Kikuchi, Jun and Takeuchi, Tsutomu and Bae, Sang-Cheol and Goldblatt, Fiona and O'Neill, Sean and Ng, Kristine and Basnayake, B. M. D. B. and Tugnet, Nicola and Tanaka, Yoshiya and Lau, Chak Sing and Li, Ning and Golder, Vera and Hoi, Alberta and Kandane-Rathnayake, Rangi and Morand, Eric and Oon, Shereen and Nikpour, Mandana (2024) Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus. Lupus Science & Medicine, 11 (2). ISSN 2053-8790, DOI https://doi.org/10.1136/lupus-2024-001217.
Full text not available from this repository.Abstract
Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity.Methods Patients with SLE enrolled in a prospective multinational cohort from March 2013 to December 2020 who were in LLDAS at least once were included. Visits that fulfilled both LLDAS and Definition of Remission in SLE (DORIS) criteria were excluded.Results 2099 patients were included, with median follow-up of 3.5 (IQR 1.3-5.8) years. At 6150 visits, patients were in LLDAS but not DORIS criteria; of these 1280 (20.8%) had some clinical activity, 3102 (50.4%) visits had serological activity only and 1768 (28.8%) visits had neither clinical nor serological activity. Multivariable regression analysis showed that compared with non-LLDAS, all three subsets of LLDAS had a protective association with flares in the ensuing 6 months and damage accrual in the ensuing 36 months. LLDAS with no clinical or serological activity had a significantly stronger protective association with severe flares in the ensuing 6 months compared with LLDAS with clinical activity (HR 0.47, 95% CI (0.27 to 0.82), p=0.007).Conclusions LLDAS without any clinical activity accounted for almost 80% of LLDAS visits. This study confirms that all subsets of LLDAS are associated with reduced flare and damage accrual. However, LLDAS without any clinical or serological activity has the strongest protective association with severe flares.
| Item Type: | Article |
|---|---|
| Funders: | National Research Foundation of Korea, University of Melbourne, APLC, Ministry of Education [Grant no. NRF-2021R1A6A1A03038899], National Health and Medical Research Council [Grant no. GNT1176538] |
| Uncontrolled Keywords: | Systemic lupus erythematosus; Epidemiology; Outcome assessment; Health care |
| Subjects: | R Medicine |
| Divisions: | Faculty of Medicine > Medicine Department |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 24 Oct 2025 12:24 |
| Last Modified: | 24 Oct 2025 12:24 |
| URI: | http://eprints.um.edu.my/id/eprint/46463 |
Actions (login required)
 |
View Item |
